Bempegaldesleukin
Bempegaldesleukin is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target interleukin-2 receptor subunit beta.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 2 | 2 | 2 | — | — | 4 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 1 | 1 | — | — | 3 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | 1 | — | — | 2 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | 1 | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | — | 1 | — | — | 1 |
| Cutaneous malignant melanoma | D000096142 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Transitional cell carcinoma | D002295 | — | — | 1 | 2 | — | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 2 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | 1 | 1 | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 1 | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 1 | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bempegaldesleukin |
| INN | bempegaldesleukin |
| Description | Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics.
|
| Classification | Protein |
| Drug class | interleukins: interleukin-2 analogues and derivatives; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1939126-74-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298058 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15140 |
| UNII ID | BNO1JG5MZC (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
IL2RB
IL2RB
Organism
Homo sapiens
Gene name
IL2RB
Gene synonyms
IL15RB
NCBI Gene ID
Protein name
interleukin-2 receptor subunit beta
Protein synonyms
CD122, CD122 antigen, high affinity IL-2 receptor beta subunit, High affinity IL-2 receptor subunit beta, IL-2 receptor subunit beta, IL-2R subunit beta, IL-2RB, interleukin 15 receptor, beta, interleukin 2 receptor, beta, Interleukin-15 receptor subunit beta, p70-75, p75
Uniprot ID
Mouse ortholog
Il2rb (16185)
interleukin-2 receptor subunit beta (Q3TZT2)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 799 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
194 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use